Современные представления о диагностике и лечении остеопороза у детей

Остеопороз (ОП) – это заболевание, характеризующееся снижением прочности кости, приводящим к повышению риска переломов. В основе хрупкости костей у детей могут лежать генетические нарушения, хронические заболевания или применение для их лечения препаратов, отрицательно влияющих на костный метаболизм. В статье рассматривается современная классификация ОП у детей, подходы к его диагностике, роль денситометрического обследования в постановке диагноза.

Основной целью профилактики и лечения ОП является достижение более высокого пика костной массы, улучшение микроархитектоники костей, а также, как и у взрослых, снижение риска переломов, предотвращение деформаций скелета, улучшение подвижности, независимости и качества жизни. Представлены рекомендации по изменению образа жизни, включая адекватное потребление кальция и витамина D, приему антирезорбтивных препаратов, а также по ведению детей с ОП.

1. Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone mass. J Bone Miner Res. 2011;26:1729-1739. doi: 10.1002/jbmr.412

2. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53:1-5. doi: 10.1016/j.ejmg.2009.10.007

3. Van Dijk FS. Genetics of osteoporosis in children. Endocr Dev. 2015;28:196-209. doi: 10.1159/000381046

4. Bregou Bourgeois A, Aubry-Rozier B, Bonafe L, Laurent-Applegate L, Pioletti DP, Zambelli PY. Osteogenesis imperfecta: From diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly. 2016;146:14322. doi: 10.4414/smw.2016.14322

5. Tournis S, Dede AD. Osteogenesis imperfecta – A clinical update. Metabolism. 2018;80:27-37. doi: 10.1016/j.metabol.2017.06.001

6. Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB. Idiopathic juvenile osteoporosis: A cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatr Rheumatol. 2013;11:1-8. doi: 10.1186/1546-0096-11-6

7. Franceschi R, Vincenzi M, Camilot M, Antoniazzi F, Freemont AJ, Adams JE, et al. Idiopathic juvenile osteoporosis: Clinical experience from a single centre and screening of LRP5 and LRP6 genes. Calcif Tissue Int. 2015;96:575-579. doi: 10.1007/s00223-015-9983-7

8. Galindo-Zavala R, Bou-Torrent R, Magallares-López B, MirPerelló C, Palmou-Fontana N, Sevilla-Pérez B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020;18(1):20. doi: 10.1186/s12969-020-0411-9

9. Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP. Epidemiology of childhood fractures in Britain: A study using the general practice research database. J Bone Miner Res. 2004;19(12):1976-1981. doi: 10.1359/JBMR.040902

10. Clark EM. The epidemiology of fractures in otherwise healthy children. Curr Osteoporos Rep. 2014;12(3):272-278. doi: 10.1007/s11914-014-0227-y

11. Mäyränpää MK, Mäkitie O, Kallio PE. Decreasing incidence and changing pattern of childhood fractures: A population-based study. J Bone Miner Res. 2010;25(12):2752-2759. doi: 10.1002/jbmr.155

12. Fiscaletti M, Coorey CP, Biggin A, Briody J, Little DG, Schindeler A, et al. Diagnosis of recurrent fracture in a pediatric cohort. Calcif Tissue Int. 2018;103(5):529-539. doi: 10.1007/s00223-018-0449-6

13. Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 2004;34(5):771-775. doi: 10.1016/j.bone.2004.01.022

14. Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: The ISCD 2013 Pediatric Official Positions. J Clin Densitom. 2014;17(2):275-280. doi: 10.1016/j.jocd.2014.01.004

15. Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008;11(1):6-21. doi: 10.1016/j.jocd.2007.12.002

16. Ward LM, Weber DR, Munns CF, Högler W, Zemel BS. A contemporary view of the definition and diagnosis of osteoporosis in children and adolescents. J Clin Endocrinol Metab. 2020;105(5):2088-2097. doi: 10.1210/clinem/dgz294

17. Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, et al.; Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Bone morbidity and recovery in children with acute lymphoblastic leukemia: Results of a six-year prospective cohort study. J Bone Miner Res. 2018;33(8):1435-1443. doi: 10.1002/jbmr.3447

18. Kocks J, Ward K, Mughal Z, Moncayo R, Adams J, Högler W. Z-score comparability of bone mineral density reference databases for children. J Clin Endocrinol Metab. 2010;95(10):4652-4659. doi: 10.1210/jc.2010-0677

19. Ma J, Siminoski K, Also N, Halton J, Ho J, Lentle B, et al.; Canadian STOPP Consortium. The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures. J Clin Endocrinol Metab. 2015;100(3):1018-1027. doi: 10.1210/jc.2014-3096

20. Bardai G, Moffatt P, Glorieux FH, Rauch F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: Diagnostic yield and mutation spectrum. Osteoporos Int. 2016;27(12):3607-3613. doi: 10.1007/s00198-016-3709-1

21. Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, et al. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int. 2017;28(2):597-608. doi: 10.1007/s00198-016-3774-5

22. Ben Amor IM, Roughley P, Glorieux FH, Rauch F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res. 2013;28(9):2001-2007. doi: 10.1002/jbmr.1942

23. Singh A, Schaeffer EK, Reilly CW. Vertebral fractures in Duchenne muscular dystrophy patients managed with deflazacort. J Pediatr Orthop. 2018;38(6):320-324. doi: 10.1097/BPO.0000000000000817

24. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000;11(4):281-294. doi: 10.1007/s001980070116

25. Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, Fuleihan GEH, Kecskemethy HH, et al. International Society for Clinical D Dualenergy X-ray absorptiometry interpretation and reporting in children and adolescents: The revised 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17:225-242. doi: 10.1016/j.jocd.2014.01.003

26. Kalkwarf HJ, Abrams SA, DiMeglio LA, Koo WW, Specker BL, Weiler H. Bone densitometry in infants and young children: The 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17:243-257. doi: 10.1016/j.jocd.2014.01.002

27. Weber DR, Boyce A, Gordon C, Hogler W, Kecskemethy HH, et al. The utility of DXA assessment at the forearm, proximal femur, and lateral distal femur, and vertebral fracture assessment in the pediatric population: 2019 ISCD official position. J Clin Densitom. 2019;22:567-589. doi: 10.1016/j.jocd.2019.07.002

28. Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, et al. Height adjustment in assessing dual energy X-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010;95(3):1265-1273. doi: 10.1210/jc.2009-2057

29. Alqahtani FF, Offiah AC. Diagnosis of osteoporotic vertebral fractures in children. Pediatr Radiol. 2019;49:283-296. doi: 10.1007/s00247-018-4279-5

30. Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148. doi: 10.1002/jbmr.5650080915

31. Crabtree NJ, Chapman S, Hogler W, Hodgson K, Chapman D, Bebbington N, et al. Vertebral fractures assessment in children: Evaluation of DXA imaging versus conventional spine radiography. Bone. 2017;97:168-174. doi: 10.1016/j.bone.2017.01.006

32. Национальная программа по оптимизации обеспеченности витаминами и минеральными веществами детей России. М.:Педиатръ;2017.

33. Национальная программа «Недостаточность витамина D у детей и подростков Российской Федерации: современные подходы к коррекции». М.:Педиатръ;2018. [National program “Vitamin D deficiency in children and adolescents of the Russian ederation: Modern approaches to correction”. Moscow:Pediatr;2018. (In Russ.)].

34. Hoyer-Kuhn H, Semler O, Stark C, Struebing N, Goebel O, Schoenau E. A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact. 2014;14:445-453.

35. Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356:1075-1076. doi: 10.1056/NEJMc062792

36. Högler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr. 2004;145:701-704. doi: 1016/j.jpeds.2004.06.066

37. Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004;35:231-234. doi: 10.1016/j.bone.2004.03.008

38. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;CD005324. doi: 10.1002/14651858.CD005324.pub2

39. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Min Res. 2004;19:1779-1786. doi: 10.1359/jbmr.040814

40. Acott PD, Wong JA, Lang BA, Crocker JF. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol. 2005;20(3):368-373. doi: 10.1007/s00467-004-1790-8

41. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagli A, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study. Arthritis Rheum. 2000;43:19601966. doi: 10.1002/1529-0131(200009)43:9<1960::AIDANR6>3.0.CO;2-J

42. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology. 2005;44:813-818. doi: 10.1093/rheumatology/keh538

43. Ward LM, Choudhury A, Alos N, Cabral DA, Rodd C, Sbrocci AM, et al. Zoledronic acid vs placebo in pediatric glucocorticoid-induced osteoporosis: A randomized, double-blind, phase 3 trial. J Clin Endocrinol Metab. 2021:106:5222-e5235. doi: 10.1210/clinem/dgab458

44. Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, et al.; Group ABMW. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54:223-233. doi: 10.1111/jpc.13768

45. Boyce AM. Denosumab: An emerging therapy in pediatric bone disorders. Curr Osteoporos Rep. 2017:15:283-292. doi: 10.1007/s11914-017-0380-1

46. Open-label extension denosumab study in children and young adults with osteogenesis imperfecta. ClinicalTrials.gov Identifier: NCT03638128. 2022.

47. Wang HD, Boyce AM, Tsai JY, Gafni RI, Farley FA, KasaVubu JZ, et al. Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab. 2014:99:891-897. doi: 10.1210/jc.2013-3081

48. Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018:103:596-603. doi: 10.1210/jc.2017-02025

49. Mariz BALA, Migliorati CA, Alves FA, Penteado FM, Carvalho NP Filho, Santos-Silva AR, et al. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child. Spec Care Dentist. 2021;41:519-525. doi: 10.1111/scd.12588

50. Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K. Hypercalcemia following discontinuation of denosumab therapy: A systematic review. Bone Rep. 2021;15:101148. doi: 10.1016/j.bonr.2021.101148

51. Ciancia S, Högler W, Sakkers RJB, Appelman-Dijkstra NM, Boot AM, Sas TCJ, et al. Osteoporosis in children and adolescents: How to treat and monitor? Eur J Pediatr. 2023;182(2):501-511. doi: 10.1007/s00431-022-04743-x

52. Study to evaluate efficacy and safety of romosozumab compared with bisphosphonates in children and adolescents with osteogenesis imperfecta. ClinicalTrials.gov Identifier: NCT05972551. 2023.

53. Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-2419. doi: 10.1002/acr.25240

54. Ward LM. Glucocorticoid-induced osteoporosis: Why kids are different. Front Endocrinol (Lausanne). 2020;11:576. doi: 10.3389/fendo.2020.00576

55. Godbout A, Tejedor I, Malivoir S, Polak M, Touraine P. Transition from pediatric to adult healthcare: Assessment of specific needs of patients with chronic endocrine conditions. Horm Res Paediatr. 2012;78:247-255. doi: 10.1159/000343818